| Title | Claps | Level | Year | L/Y |
|---|---|---|---|---|
|
An orally administered butyrate‐releasing derivative reduces neutrophil recruitment and inflammation in dextran sulphate sodium‐induced murine colitis
11 auth. R. Simeoli, G. Mattace Raso, C. Pirozzi, A. Lama, A. Santoro, R. Russo, ...
Butyrate has shown benefits in inflammatory bowel diseases. However, it is not often administered orally because of its rancid smell and unpleasant taste. The efficacy of a more palatable butyrate‐releasing derivative, N‐(1‐carbamoyl‐2‐phenylethyl) …
Butyrate has shown benefits in inflammatory bowel diseases. However, it is not often administered orally because of its rancid smell and unpleasant taste. The efficacy of a more palatable butyrate‐releasing derivative, N‐(1‐carbamoyl‐2‐phenylethyl) butyramide (FBA), was evaluated in a mouse model of colitis induced by dextran sodium sulphate (DSS).
Published in
British Journal of Pharmacology
|
11
|
6 | 2017 |
Social Media Posts